The Recall Desk
SevereFDA (Drugs)·D-395-2014·Announced 2014-01-08

Hospira Recalls Bupivacaine Hydrochloride Vials Due to Sterility Concerns

Hospira Inc. is recalling 65,109 vials of Bupivacaine Hydrochloride with Epinephrine due to a potential breach in the aseptic process caused by equipment failure.

What this means for you

Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.

Our severity reasoning: The recall is classified as FDA Class II. Per the rubric, an FDA Class II recall involving a drug with a potential sterility breach (risk of serious infection) falls under the 'Severe' category, as it represents a significant risk of harm even without reported hospitalizations.

Plain-English summary

Hospira Inc. is recalling 65,109 vials of Bupivacaine Hydrochloride 0.5% and Epinephrine 1:200,000 Injection, 50 mL, Multiple-dose Fliptop Vial. The affected product is identified by NDC #0409-9046-01 and includes Lot #32-484-EV and Lot #32-485-EV, both with an expiration date of 2/2015.

The recall was initiated because an equipment failure led to a potential breach in the aseptic process, resulting in a lack of assurance of sterility. The product was distributed nationwide in the United States.

Healthcare providers and patients should stop using the affected vials and contact Hospira Inc. for further instructions or to arrange for a return or replacement of the product.

The recalled product

Product
BUPIVACAINE HYDROCHLORIDE (BUPIVACAINE HYDROCHLORIDE)
Brand
BUPIVACAINE HYDROCHLORIDE
Manufacturer
Hospira Inc.
Affected units
65,109

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (2)

  • Lot #32-484-EV
  • 32-485-EV Exp: 2/2015.

Distribution

Distributed nationwide across the United States.